Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
Status:
Terminated
Trial end date:
2019-05-17
Target enrollment:
Participant gender:
Summary
Recently results have shown that Bevacizumab is active both in monotherapy and in combination
therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the
addition of neoadjuvant bevacizumab improves the response and whether this affects the
evolution of patients.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Investigación en Cáncer de Ovario